Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year ...

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 ... due to the normal 30-day timing between a Cologuard order and a completed test. Second, disruption ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Exact Sciences Corp (NASDAQ ... Milton negatively affected Cologuard orders and results, particularly impacting the fourth quarter due to the 30-day timing between order and test completion.

“Exact Sciences is pleased to share new modeling data which demonstrates the Cologuard Plus test as an ... of our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports ...

The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common stock. (3) Represents acquisition and related integration costs incurred ...